headerphoto


Dear Patients, Medical Specialists or HCC-Experts,
Dear Guests and Visitors of this website,

The SORAMIC clinical trial[1] represents something new and very unique in the world of medicine in general as well as in the treatment of liver cell carncer (HCC) in particular. This project represents an effort to combine the expertise of Hepatologists, Oncologists, Diagnostic and Interventional Radiologists, Nuclear medicine specialists, Surgeons and Pathologists to invent and prove the finest therapeutic combinations for diagnosis and treatment of hepatocellular cancer: a fine example of interdisciplinary work to achieve the best imaginable results for our patients.

SORAMIC combines the most promising novel diagnostic and therapeutic approaches in HCC treatment available to date: diagnosis with hepatocyte specific contrast agent Primovist®; microtherapy with SIRT (Y90 radioembolisation) or radiofrequency ablation; and systemic treatment with thyrosinekinase inhibitor Sorafenib.

SORAMIC is sponsored by the Magdeburg University Hospital jointly in the Department of Radiology and Nuclear Medicine and in the Department of Gastroenterology, Hepatology and Infectious Diseases. SORAMIC is supported financially by Bayer AG and Sirtex Medical Europe.

We cordially invite you to learn about the the SORAMIC clinical trial on this website. You will obtain some in depth information on the study design as well as on the topic of hepatocellular carcinoma in general. You will also have the opportunity to get to know the minds behind the study. SORAMIC is also listed on http://clinicaltrials.gov.

The trial started on 28 December 2010. Mid November 2016, the palliative arm reached its planned study endpoint, which has brought the the unique study SORAMIC to a close.

Sincerely yours,

Malfertheinerneud2.jpg

Malfertheinerneud2.jpg

Prof Dr J Ricke                        Prof Dr P Malfertheiner

 

Read the latest SORAMIC newsletter here!

 


[1] Full title: "Evaluation of Sorafenib in combination with local micro-therapy guided by Primovist® enhanced MRI in patients with hepatocellular carcinoma"